Drug Profile

SBT 77 7101

Alternative Names: SBT-77-7101

Latest Information Update: 21 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sonoma Biotherapeutics
Class CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Regulatory T-lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Hidradenitis suppurativa; Rheumatoid arthritis

Most Recent Events

22 Jul 2025 Sonoma Biotherapeutics initiates a an observational trial in USA (NCT07123038)
11 Jun 2025 Adverse events data from the phase I REGULATE-RA trial in Rheumatoid arthritis presented at the 26^th Annual Congress of the European League Against Rheumatism (EULAR-2025)
12 Apr 2024 Phase-I clinical trials in Hidradenitis suppurativa in USA (Parenteral) (NCT06361836)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com